Lacosamide 1a Farma (Lacosamide)

Lacosamide is an antiepileptic drug that acts on neuronal sodium channels to control seizure activity.

• Partial‑onset seizures: reduces the frequency and severity of focal seizures.
• Epilepsy (adjunct therapy): helps achieve better overall seizure control when added to existing regimens.
• Refractory focal epilepsy: provides an additional option for patients whose seizures are not controlled by other agents.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and decreasing hyper‑excitability. By selectively targeting the slow inactivation phase, it limits repetitive firing of neurons without markedly affecting normal conduction, thereby reducing the propagation of epileptic discharges.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: mild to moderate stomach upset.
• Headache: intermittent or persistent pain.
• Fatigue: increased tiredness or lack of energy.
• Blurred vision: temporary visual disturbances.
• Diplopia: double vision in some patients.

Serious or Rare Side Effects

• Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmias.
• Suicidal ideation: emergence of thoughts of self‑harm.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Respiratory depression: especially when combined with other CNS depressants.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Blood dyscrasias: rare cases of agranulocytosis or thrombocytopenia.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal impairment: adjust dose and monitor renal function.
• Hepatic impairment: consider dose reduction and observe liver enzymes.
• Cardiac conduction disorders: obtain baseline ECG and monitor PR interval.
• Pregnancy: risk unknown; discuss benefits and risks with the prescriber.
• Concomitant antiepileptics: monitor for additive CNS effects.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medications, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels.
• Drugs that prolong PR interval (e.g., quinidine, amiodarone): increase risk of cardiac arrhythmia.
• Other sodium‑channel blockers (e.g., lamotrigine, oxcarbazepine): may enhance neurotoxicity.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: lacosamide may lower hormonal efficacy, requiring additional contraception.
• Valproate or other antiepileptics: monitor for increased adverse effects.
• Alcohol: may potentiate central nervous system depression, leading to heightened drowsiness.